Investigation of the factors influencing the release rates of cyclosporin A-loaded micro- and nanoparticles prepared by high-pressure homogenizer

Journal of Controlled Release

Volumn 84, Issue 3, 2002, Pages 115-123

  Lee, Woo kyoung ^a   Park, Jong Yeun ^a   Yang, Eun Hee ^a   Suh, Hearan ^a   Kim, Sung Hoon ^a   Chung, Doo Soo ^a   Choi, Kihwan ^a   Yang, Chul Woo ^b   Park, Jong Sang ^a  

^a Seoul National University   (South Korea)

^b The Catholic University of Korea   (South Korea)

Author keywords

Cyclosporin A (CyA); High pressure homogenizer; Nanoparticles; Poly(D,L lactic acid) (PLA); Poly(D,L lactide co glycolic acid) (PLGA)

Indexed keywords

COPOLYMER; CYCLOSPORIN A; ETHYLMYRISTATE; FATTY ACID ESTER; GLYCOLIC ACID; MYRISTIC ACID DERIVATIVE; NANOPARTICLE; OIL; POLYGLACTIN; POLYLACTIC ACID; POLYMER; SOLVENT; UNCLASSIFIED DRUG; WATER; CYCLOSPORIN; LACTIC ACID; MICROSPHERE; MYRISTIC ACID ETHYL ESTER; POLYGLYCOLIC ACID; POLYLACTIC ACID POLYGLYCOLIC ACID COPOLYMER; POLYLACTIC ACID-POLYGLYCOLIC ACID COPOLYMER;

ARTICLE; DIALYSIS; DRUG FORMULATION; DRUG RELEASE; ENCAPSULATION; EVAPORATION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HYPERBARIC OXYGEN; IN VITRO STUDY; LIGHT SCATTERING; PARTICLE SIZE; PRIORITY JOURNAL; SCANNING ELECTRON MICROSCOPY; CHEMISTRY; INSTRUMENTATION; KINETICS; METHODOLOGY; NANOTECHNOLOGY; PRESSURE; SOLUBILITY; TIME;

CYCLOSPORINE; DRUG COMPOUNDING; KINETICS; LACTIC ACID; MICROSCOPY, ELECTRON, SCANNING; MICROSPHERES; MYRISTATES; NANOTECHNOLOGY; PARTICLE SIZE; POLYGLYCOLIC ACID; POLYMERS; PRESSURE; SOLUBILITY; TIME FACTORS;

EID: 0037028069     PISSN: 01683659     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0168-3659(02)00239-0     Document Type: Article

References (24)

1. Cohen D.J., Loertscher R., Rubin M.F. Cyclosporin A: a new immunosuppressive agent for organ transplantation. Ann. Intern. Med. 101:1984;667-682.
2. Richardson C., Emery P. Clinical use of cyclosporin in rheumatoid arthritis. Drugs. 50:(1):1995;26-36.
3. Sajjadi H., Soheilian M., Ahmadieh H., Hassanein K., Parvin M., Azarmina M., Ehyaee V., Amiransari B. Low dose cyclosporin-A therapy in Behcet's disease. J. Ocul. Pharmacol. 10:1994;553-560.
4. Mehta M., Venkataramanan R., Buckart G.J. Effects of bile on cyclosporin absorption in liver transplant patients. Br. J. Clin. Pharmacol. 25:1984;579-584.
5. Yee G.C., McGuire T.R. Pharmacokinetic drug interactions with cyclosporin (part I). Clin. Pharmacokinet. 19:1990;319-332.
6. Campana C., Regazzi M.B., Buggia I., Molinaro M. Clinically significant drug interactions with cyclosporin. An update. Clin. Pharmacokinet. 30:1996;141-179.
7. Zachariae H. Renal toxicity of long-term cyclosporin. Scand. J. Rheumatol. 28:1999;65-68.
8. Gijtenbeek J.M., van den Bent M.J., Vecht C.J. Cyclosporine neurotoxicity: a review. J. Neurol. 246:1999;339-346.
9. Nankivell B.J., Hibbins M., Chapman J.R. Diagnostic utility of whole blood cyclosporine measurements in renal transplantation using triple therapy. Transplantation. 58:1994;989-996.
10. Kovarik J.M., Mueller E.A., Van Bree J.B., Tetzloff W., Kutz K. Reduced inter- and intraindividual variability in cyclosporine pharmacokinetics from a microemulsion formulation. J. Pharm. Sci. 83:1994;444-446.
11. Olyaei A.J. Switching between cyclosporin formulations: what are the risks? Drug Safety. 16:1997;366-373.
12. Wu C.Y., Bennet L.Z., Bebert M.F., Gupta S.K., Rowland M., Gomez D.Y., Whacher V.J. Differentiation of absorption and Ærst-pass gut and hepatic metabolism in humans: studies with cyclosporine. Clin. Pharmacol. Ther. 58:1995;492-497.
13. Takada K., Shibata N., Yoshimura H., Masuda Y., Yoshikawa Y., Muranshi S., Oka T. Promotion of the selective lymphatic delivery of cyclosporin A by lipid-surfactant mixed micelles. J. Pharmocobiodyn. 8:1985;320-323.
14. Molpeceres J., Chacon M., Guzman M., Berges L., Aberturas M.R. Increased oral bioavailability of cyclosporine incorporated in polycaprolactone nanoparticles. 3rd Spanish-Portuguese Conference on Controlled Drug Delivery, Lisbon :1998;127-128.
15. Molpeceres J., Chacon M., Guzman M., Berges L., Aberturas M.R. A polycaprolactone nanoparticle formulation of cyclosporine improves the prediction of area under the curve using a limited sampling strategy. Int. J. Pharm. 187:1999;101-113.
16. Sanchez A., Alonso M.J. Poly (D,L-lactide-co-glycolide) micro and nanospheres as a way to prolong blood/plasma levels of subcutaneously injected cyclosporin A. Eur. J. Pharm. Biopharm. 41:(1):1995;31-37.
17. Sanchez A., Seoane R., Quireza O., Alonso M.J. In vivo study of the tissue distribution and immunosuppressive response of cyclosporin A-loaded polyester micro- and nanospheres. Drug Deliv. 2:1995;21-28.
18. Urata T., Arimori K., Nakano M. Modification of release rates of cyclosporin A from poly (L-lactic acid) microspheres by fatty acid esters and in-vivo evaluation of the microspheres. J. Control. Release. 58:1999;133-141.
19. Tobio M., Sanchez A., Vila A., Soriano I., Evora C., Vila-Jato J.L., Alonso M.J. The role of PEG on the stability in digestive fluids and in vivo fate of PEG-PLA nanoparticles following oral administration. Colloids Surf. B: Biointerf. 18:2000;315-323.
20. Gref R., Quellec P., Sanchez A., Calvo P., Dellacherie E., Alonso M.J. Development and characterization of CyA-loaded poly(lactic acid)-poly(ethylene glycol)PEG micro- and nanoparticles. Comparison with conventional PLA particulate carriers. Eur. J. Pharm. Biopharm. 51:2001;111-118.
21. Lamprecht A., Ubrich N., Hombreiro Pe'rez M., Lehr C.M., Hoffman M., Maincent P. Biodegradable monodispersed nanoparticles prepared by pressure homogenization-emulsification. Int. J. Pharm. 184:1999;97-105.
22. Peppas N.A. Analysis of Fickian and non-Fickian drug release from polymers. Pharm. Acta Helv. 60:(4):1985;110-111.
23. Baker R.W., Lonsdale H.K. Tanquary A.C., Lacey R.E. Controlled Release of Biologically Active Agent. 47:1974;15-71 Plenum Press, New York.
24. Kim W.U., Lee W., Ryoo J.W., Kim S.H., Kim J., Youn J., Min S.Y., Bae E.Y., Hwang S.Y., Park S.H., Cho C.S., Park J.S., Kim H.Y. Suppression of collagen-induced arthritis by single administration of poly(lactic-co-glycolic acid) nanoparticles entrapping type II collagen: a novel treatment strategy for induction of oral tolerance. Arthritis Rheum. 46:(4):2002;1109-1120.